This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a randomised controlled trial (RCT) that was undertaken in multiple sites. The patients were randomised to any of the two groups, stratified by clinical site and by whether the operator planned to use a glycoprotein IIb/IIIa receptor antagonist. An independent clinical events committee who were blinded to the treatment assignment reviewed all end points. The patients were followed up for 30 days. The authors reported no loss to follow-up.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The health outcomes were MI, haemorrhagic complications, any repeat revascularisation and death. MI was defined as an elevation of creatinine kinase-MB (CKMB) greater than three times the upper limit of normal at any time during the follow-up period. Large MI was defined prospectively as any MI with a peak CKMB greater than 5 times the upper limit of normal, or any Q-wave MI. The authors assumed that only large MIs would adversely affect long-term prognosis after PCI. Haemorrhagic complications included the need for vascular surgical repair, ultrasound-guided compression, or bleeding requiring transfusion. The baseline characteristics of the two treatment groups were well-matched, with patients shown to be comparable in terms of age, gender and prognostic features.
Effectiveness results
There was no difference in in-hospital mortality between the GuardWire and control groups (0.7% versus 1.0%; p=0.72).
Patients randomised to the GuardWire group had a significantly lower incidence of periprocedural MI during the index hospitalisation (8.4% versus 13.9%; p=0.01). In addition, the GuardWire group was associated with a modest reduction in the incidence of bleeding complications compared with conventional treatment (5.4% versus 7.1%; p=0.38).
Between hospital discharge and 30-day follow-up, there were trends toward reduced rates of death (0.3% versus 1.6%; p=0.06) and nonfatal MI (0.5% versus 1.6%; p=0.17) in the GuardWire group.
When these results were combined with the observed in-hospital outcomes, use of the GuardWire was associated with a 42% reduction in the 30-day risk of death or any MI (95% confidence interval, CI: 17 -65) and a 44% reduction in the risk of death or large MI (95% CI: 10 -68). There were no significant differences in the rates of repeat revascularisation procedures.
Clinical conclusions
The GuardWire balloon occlusion device was effective in reducing mortality and MI in comparison with conventional PCI.
Modelling
As the empiric outcomes data were only collected for the 30-day follow-up period, the authors developed a probabilistic model to project long-term survival beyond the study observation period, contingent on the observed 30-day outcomes. The measures of benefits used were combined deaths and MIs avoided during the 30-day trial period, and the lifetime life-years gained. The life expectancy was derived from a long-term survival model (probabilistic model). The life expectancy was discounted at a rate of 3% per year.
Measure of benefits used in the economic analysis

Direct costs
The total costs and resource use were reported separately. The direct costs included in the analysis were those to the health care system. These were the costs of initial and repeat procedures, hospitalisation, doctors' fees and follow-up costs. The cost of the GuardWire device was based on its current sales price. The costs of additional disposable equipment, overheads and depreciation for the cardiac catheterisation laboratory were estimated on the basis of the average cost per procedure in the authors' setting, and adjusted for actual procedure duration. All of the other hospital costs were determined using a top-down accounting method based on each hospital's Medicare cost report. Billing data were obtained for 776 admissions during the 30-day study period. The hospital costs were determined by multiplying itemised hospital charges by the cost-centre-specific cost-to-charge ratio. For those admissions for which billing data were not available (n=123), non-procedural hospital costs were imputed on the basis of a linear regression model, which was developed using the hospital admissions for which complete billing information was available. Other costs such as physician office visits, emergency department visits, echocardiograms and stress tests, were estimated by patient selfreport and were calculated on the basis of 2001 Medicare reimbursement rates. Physician's fees were based on the 2001 Medicare fee schedule. Discounting was irrelevant, as all the costs were incurred during a short time, and was therefore not performed. All the costs were converted to 2001 dollars using the medical care component of the Consumer Price Index. The study reported the average costs.
Statistical analysis of costs
The costs and the resource use data were treated stochastically. Data were compared using the Wilcoxon rank-sum test.
To define the factors that contributed to the net cost of GuardWire treatment more precisely, the authors used multivariable linear regression to determine the impact of clinical outcomes, complications and other factors on the initial hospital costs.
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
The CIs for the cost-effectiveness ratios were estimated by the bootstrap method, using 1,000 re-samples of the study population. In addition, although future costs beyond the 30-day trial period were not included in the primary analysis, these additional costs were considered in sensitivity analyses. The authors also carried out sensitivity analyses by varying the assumptions concerning the long-term outcomes, and by varying the relative risk of death or MI. Lastly, the authors conducted sub-group analyses according to angiographic, clinical and treatment-specific factors.
Estimated benefits used in the economic analysis
Use of the GuardWire was associated with a 42% reduction in the 30-day risk of death or any MI (95% CI: 17 -65) and a 44% reduction in the risk of death or large MI (95% CI: 10 -68).
The mean life expectancy (undiscounted) was 11.38 years for the GuardWire group and 11.16 years for the conventional therapy group, a difference of 0.22 years. After discounting, the life expectancy difference was reduced to 0.17 years (95% CI: 0.04 -0.29).
Validity of estimate of costs
The perspective of the analysis was not explicitly stated, but was consistent with that of the health care system. All the cost categories relevant to the perspective adopted were included in the analysis, and all the relevant costs appear to have been included. The costs and the quantities were reported separately, which will increase the generalisability of the authors' results to other settings. Resource use was derived from the single study, with appropriate statistical techniques being used to test for any significant differences between the two groups. The unit costs were derived from several sources, with the majority being derived from Medicare charges. Although charges were used, the authors adjusted charges to the specific cost-to-charge ratio, so that these costs would more accurately depict the actual cost of providing an intervention. The authors performed a multiple linear regression to identify the predictors of initial hospital costs.
Discounting was not relevant, as all the costs were incurred during a short time, and was not performed. The price year was appropriately reported, which will aide any possible inflation exercises.
